NCT01318031 - Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Healthy Volunteers

Interventions

DRUG

Period 1

Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.

DRUG

Period 2

Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven